Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23297056 | 1.00 | KMT2A (0.33) | KMT2AKDM4ESMN1; SMN2ACHENPC1 | |
| SCHEMBL23297059 | 1.00 | KMT2A (0.33) | KMT2AKDM4ESMN1; SMN2ACHENPC1 | |
| SCHEMBL23341380 | 0.81 | TP53 (0.47) | KDM4ESMN1; SMN2 | |
| SCHEMBL28789206 | 0.81 | TP53 (0.47) | KDM4ESMN1; SMN2 | |
| SCHEMBL23341382 | 0.81 | TP53 (0.47) | KDM4ESMN1; SMN2 | |
| SCHEMBL23336239 | 0.77 | TP53 (0.35) | — | |
| SCHEMBL25756363 | 0.77 | TP53 (0.35) | — | |
| SCHEMBL23341379 | 0.77 | TP53 (0.35) | — | |
| Hydrochloric Acid SCHEMBL23296918 | 0.76 | TP53 (0.34) | — | |
| Hydrochloric Acid SCHEMBL23297104 | 0.76 | TP53 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034728-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-114761086-A | Pyridazinones as PARP7 inhibitors | 里邦医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-05-06 | — | — | US | disclosed |
| WO-2021087025-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | KMT2A 1137/4885KDM4E 929/4885SMN1; SMN2 4309/4885 |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | PARP2, PARP1, PARP4 | KMT2A 1817/4885KDM4E 1264/4885SMN1; SMN2 4177/4885 |
| US-20240034728-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | KMT2A 1137/4885KDM4E 929/4885SMN1; SMN2 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.